<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046094</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2019-IVC_CarboGem</org_study_id>
    <nct_id>NCT04046094</nct_id>
  </id_info>
  <brief_title>Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients</brief_title>
  <official_title>IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is a common disease with high rates of mortality, especially at advanced&#xD;
      stages. Neo-adjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy is&#xD;
      considered standard of care for patients with muscle invasive disease, as NAC improves&#xD;
      surgical outcomes in these patients. However, some patients are ineligible for&#xD;
      cisplatin-based chemotherapy due to other medical issues. Although a combination of&#xD;
      carboplatin and gemcitabine has been used with limited success, most patients proceed&#xD;
      directly to cystectomy without realizing the potential survival benefit afforded by NAC.&#xD;
      Intravenous ascorbate (vitamin C) administration (IVC) has been shown to improve both&#xD;
      carboplatin and gemcitabine-based therapy in other models. This trial will add IVC to&#xD;
      gemcitabine/carboplatin chemotherapy to evaluate whether co-treatment will increase&#xD;
      therapeutic efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Treatment Pathological Staging</measure>
    <time_frame>10 weeks</time_frame>
    <description>Pre and Post treatment specimen pathology results evaluated per American Joint Committee on Cancer (AJCC) staging guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall change in patient-reported quality of life outcomes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluated per Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) version 4 - quality of life (QOL) questionnaire scores&#xD;
FACT-Bl total score range is 0-156, derived by the sum of the sub-scales. Higher scores indicate better QOL.&#xD;
FACT-Bl includes five sub-scales:&#xD;
Physical Well-being (PWB), score range of 0-28&#xD;
Social/Family Well-being (SWB), score range of 0-28&#xD;
Emotional Well-being (EWB), score range of 0-24&#xD;
Functional Well-being (FWB), score range of 0-28&#xD;
Bladder Cancer Subscale (BlCS), score range of 0-48&#xD;
Note: Negatively stated items are reversed by subtracting the response from &quot;4&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival rate (DFS) among participants</measure>
    <time_frame>5 years</time_frame>
    <description>Medical Record</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>IV Ascorbic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Ascorbic Acid Intravenous</description>
    <arm_group_label>IV Ascorbic Acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 -- 2&#xD;
&#xD;
          -  Cisplatin-ineligible, muscle invasive bladder cancer&#xD;
&#xD;
          -  Adequate organ and marrow functions&#xD;
&#xD;
          -  Women of child-bearing potential and men with partners of child-bearing potential must&#xD;
             agree to use protocol specified forms of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient simultaneously enrolled in any therapeutic clinical trial&#xD;
&#xD;
          -  Current or anticipated use of other investigational agents while participating in this&#xD;
             study&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Pregnant or breast feeding. There is a potential for congenital abnormalities and for&#xD;
             this regimen to harm breast feeding infants&#xD;
&#xD;
          -  Histology of pure adenocarcinoma, pure squamous cell carcinoma, or pure small cell&#xD;
             carcinoma in the TURBT sample&#xD;
&#xD;
          -  Prior systemic chemotherapy (prior intravesical therapy is allowed) and/ or prior&#xD;
             radiation therapy to the urinary bladder&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Current consumption of tobacco products&#xD;
&#xD;
          -  History of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Taylor, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Nurse Navigator</last_name>
    <phone>913-945-7552</phone>
    <email>ctnursenav@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center (KUCC)</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steve Williamson, MD</last_name>
      <phone>913-588-3808</phone>
      <email>SWILLIAM@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>John Taylor</investigator_full_name>
    <investigator_title>Professor, Director of Basic Urologic Research, Co-Leader of D3ET</investigator_title>
  </responsible_party>
  <keyword>Intravenous (IV) Ascorbic Acid (Vitamin C)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

